TheraPanacea
Alexandre Favre has extensive work experience, starting in 2002 with Mazars as a Senior Manager in Transaction Services. Alexandre then joined Sanofi in 2010, where they held various finance roles including Head of Financial Investments & Legal Restructuring, CFO Nordics & Baltics and Head of Finance Diabetes Cardiovascular. Their most recent role at Sanofi was Head of Finance Clinical Development. In 2022, they became the Chief Financial Officer at TheraPanacea.
Alexandre Favre attended École Polytechnique from 1997 to 2000. Alexandre did not pursue a specific degree or field of study during this time. Following their education at École Polytechnique, they enrolled at Mines Paris from 2000 to 2002. No specific degree or field of study was mentioned during their tenure at Mines Paris.
TheraPanacea
TheraPanacea is an innovative information technology company devoted to unlocking the power of AI-based solutions to drive innovation in healthcare. A spin-off of University Paris-Saclay, TheraPanacea works in close cooperation with the most prominent healthcare facilities to combine the power of its proprietary platforms with clinical domain-knowledge. Today, ART-Plan™, TheraPanacea dedicated suite for radio-oncology, is used by more than 60 cancer centres across Europe, Africa, Middle-East and the US and is helping to improve care for more than 60,000 patients every year. TheraPanacea also develops and operates the ART-Omics™ platform enabling pharmaceutical companies to accelerate clinical research by harnessing AI-based multi-modality biomarker discovery in clinical trials and their effective integration within the clinical workflow at scale in the form of certified medical devices.